Thermo Fisher Sells Microbiology Unit for Over $1 Billion

Thermo Fisher Scientific has agreed to sell its microbiology business unit to private equity firm Astorg for more than $1 billion. The deal is seen as part of the company's portfolio optimization strategy. The sale reflects Thermo Fisher's plan to divest non-core assets and focus on areas with higher growth potential. The microbiology unit offers products used in clinical and industrial testing. Astorg aims to expand its presence in the healthcare sector through this acquisition. The transaction is expected to close in the first half of 2025, subject to regulatory approvals. Thermo Fisher plans to use the proceeds from the transaction for debt reduction and strategic investments. The company has recently been focusing on growth in the life sciences and diagnostics fields. This is not investment advice.

📊 TMO — Piyasa Yorumu

■ neutral · 60%

The news can be evaluated within the company's portfolio optimization efforts, but it is difficult to determine a clear direction in the short term. Technical indicators are weak: RSI is near oversold territory at 35, MACD is below the signal line, and the price is below both the 20-day and 50-day moving averages. The sale news could boost cash flow, but despite the size of the unit sale, market reaction may remain limited. In the short term, the price is expected to consolidate at current levels or show a slight recovery.

RSI 14

35.8

MACD

-2.35

24h Δ

-0.50%

📊 GOOGL — Piyasa Yorumu

■ neutral · 30%

The market impact may be limited as the news headline is not directly related to GOOGL. Technical indicators show the RSI approaching overbought territory at 67.7, while the MACD has fallen below its signal line. The 9.76% gain over the past 24 hours could increase the risk of profit-taking in the short term. The price trading near the 20-day moving average does not provide a clear directional signal. Therefore, a sideways trend is expected in the near term.

RSI 14

67.7

MACD

6.14

24h Δ

9.76%

Canlı Grafikler